2021
DOI: 10.1038/s41409-021-01460-1
|View full text |Cite
|
Sign up to set email alerts
|

A prospective pilot study of a novel alemtuzumab target concentration intervention strategy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
7
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 6 publications
(8 citation statements)
references
References 9 publications
1
7
0
Order By: Relevance
“…For ATLG, this still needs to be determined, but a correlation between exposure and outcome seems most likely. High alemtuzumab levels also seem to be correlated with delayed immune reconstitution, but data is still scarce, and more research is needed in order to define a therapeutic target and an optimal dosing regimen ( Marsh et al, 2016 ; Bhoopalan et al, 2020 ; Arnold et al, 2021 ; Dong et al, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…For ATLG, this still needs to be determined, but a correlation between exposure and outcome seems most likely. High alemtuzumab levels also seem to be correlated with delayed immune reconstitution, but data is still scarce, and more research is needed in order to define a therapeutic target and an optimal dosing regimen ( Marsh et al, 2016 ; Bhoopalan et al, 2020 ; Arnold et al, 2021 ; Dong et al, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
“…The publication of Dong et al described the results of a patient cohort of 29 patients with non-malignant disease undergoing HSCT [median age 6.4 years (range 0.28–21.4)], who were enrolled in two different studies ( Marsh et al, 2017 ; Arnold et al, 2021 ). Alemtuzumab was given as a total dose of 1 mg/kg divided over days -14 to -10 in study 1 ( n = 17) and in study 2 as a total dose of 0.5–0.6 mg/kg.…”
Section: Serotherapymentioning
confidence: 99%
“…Still, alemtuzumab is currently used for the indication of hyperinflammation, with subcutaneous low dosing implemented to overcome slow or absent T-cell recovery (Bhatt et al, 2020). TDM of alemtuzumab is mainly focused on preventing underdosing (Arnold et al, 2021). From a pharmacokinetic perspective, exposure of ATG is easier to control given the higher clearance compared to alemtuzumab.…”
Section: Discussionmentioning
confidence: 99%
“…Hence, a therapeutic range of 0.15‐0.6 mg/L has been proposed for HSCT recipients, 12 demonstrating increasingly clear relations of alemtuzumab exposure with lymphocyte recovery and clinical outcomes in this setting. These findings have supported a personalized approach, with body size 9–12 and baseline lymphocyte count 9,11 as potential markers to guide individualized alemtuzumab therapy in HSCT, and provided a rationale for exploring a model‐informed therapeutic drug monitoring (TDM)‐guided dosing strategy 18 . Similarly, an exposure‐response relationship has been suggested for alemtuzumab in CLL, 14 in which the probability of treatment response was dependent on alemtuzumab exposure.…”
Section: Introductionmentioning
confidence: 78%
“…These findings have supported a personalized approach, with body size [9][10][11][12] and baseline lymphocyte count 9,11 as potential markers to guide individualized alemtuzumab therapy in HSCT, and provided a rationale for exploring a model-informed therapeutic drug monitoring (TDM)guided dosing strategy. 18 Similarly, an exposure-response relationship has been suggested for alemtuzumab in CLL, 14 in which the probability of treatment response was dependent on alemtuzumab exposure.…”
Section: Introductionmentioning
confidence: 92%